Scienza e Tecnologia
PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate PEP-010
PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy's innovative ell enetrating & nterfering eptide (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms, without altering physiological mechanisms.
PEP-Therapy will use the funds to finance the Phase I a/b clinical trial of PEP-010, PEP-Therapy's lead candidate, for the treatment of advanced solid tumors. The first part of the Series A, which closed in April 2021 , will finance the Phase Ia dose escalation part of the study, with the additional funds being used for the development of PEP-010 until the end of the expansion cohorts, Phase Ib.
PEP-Therapy expects to generate promising clinical data from this study, particularly in two indications: metastatic triple negative breast cancer and platinum resistant ovarian cancer. Patients with these two types of solid tumors have a poor prognosis and limited therapeutic alternatives.
said: " "
, commented
, added "
In addition, PEP-Therapy and its clinical partners, Institut Curie and Gustave Roussy , previously received a €2.9 million grant from the French state innovation fund – (FUI) – to finance nonclinical and early clinical development of PEP-010.
PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company's innovative ell enetrating and nterfering eptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Anaxago, i&i Prague , Italian Angels for Growth (IAG), Doorway, Magna Capital Partners (MCP), Business Angels des Grandes Ecoles (BADGE), Seventure Partners (Quadrivium 1 Seed Fund), and Dr. Bernard Majoie (former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation).
For more information, please visit www.pep-therapy.com
Founded in 2012, Anaxago Venture Capital is a digital VC firm specialised in Healthtech & Biotech, Proptech, Fintech and Impact investing. Anaxago Venture Capital has financed more than 45 companies since its creation.
Find more on: https://venturecapital.anaxago.com/
Contact: gaston@anaxago.com
i&i Prague focuses on scouting and supporting innovative technologies in the field of drug development, diagnostics and medical devices. It supports the foundation of spin-off companies and invests in their pre-seed to Series A phases. So far, i&i Prague has supported more than 10 spin-off companies from 4 countries with total investment of almost €3.0 Million. i&i Prague also supports the commercialization of innovative technologies from over 15 research institutions and universities in the Czech Republic and abroad.
For further information visit: www.iniprague.com
Business Angels des Grandes Ecoles (BADGE), created in 2004, is a leading French Business Angels association with more than 280 members, and having participated in 21 fundraisings in 2020 of a combined value of over €5.3 million.
Its members are recognized leaders in all sectors of the industry and are willing to finance and support young innovative companies with high growth potential.
BADGE aims to:
BADGE has thus financed more than 185 young companies since its creation.
Find more on: www.business-angels.info
Antoine Prestat, CEO & co-founder
hello.pep@pep-therapy.com
+33 1 81 70 76 82
Sylvie Berrebi , David Dible
PEP-Therapy@medistrava.com
+44 (0)7714 306525